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Introduction 
 
Since the introduction of the penicillin, antibiotics have been regarded as a game changer in 
medicine. Alexander Fleming1 warned the global community in his Nobel Prize speech in 1945 
about the factor that bacteria could become resistant to antibiotics. (WHO, 2014: 23) This is an 
evolutionary process for microorganism to fight back and eventually become resistant to the drug.  
 
The growing resistance of many infectious diseases to antibiotics presents one of the biggest public 
health challenges to modern society. It’s a paradox that medical research now has become a victim 
of it’s own success. These miracle drugs that have saved millions of lives are loosing their ability to 
cure due to overuse and misuse. (Laxminarayan, Malani, 2007: 13) The first time a patient was 
treated successfully with penicillin was in 1941; the person was suffering from an infection, which 
had emerged from a simple thorn scratch. People forget that our ability to treat bacterial infections 
goes back only 74 years. (Laxminarayan, Malani, 2007: 32) 
 
Due to countries difference in economic, cultural and behaviour patterns, antibiotic resistance is 
driven by many different factors globally. Recent globalization has enabled resistance to travel over 
boarders due to international trade and collaboration on many levels. Both developed and 
developing countries are witnessing the consequences of the resistance. The history of diseases has 
showed that diseases, which affect the poorer part of the world, don’t get the same attention when it 
comes to developing cures for them.  
 
																																																								
1 Alexander Fleming invented the penicillin, and said that every time a doctor gives a patient who does not need 
pencillin he is killing another. 
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This project will investigate: Why we have a resistance problem. What policies are needed in order 
to develop new antibiotics while making sure that access to them is possible for developing 
countries.    
Methodology 
 
Antibiotic resistance is a very broad topic touching many areas that are interconnected. The 
methodology of the project is to investigate the problem broadly, touching different aspects of 
antibiotic resistance. The two theories are complementing each other and give a good understanding 
of why we have this power relation between developed countries and developing countries. When it 
comes to access to antibiotics this power relation has historically had a negative influence for the 
developing countries.     
 
The project has a theoretical research method approach. The literature consists of books and reports 
conducted by scholars and experts and are fundamental for the project. Internet sources are was 
used to complement and was necessary for reports and documents from the World Health 
Organization.  
 
Different reports on antibiotic resistance was used to get a more objective and broad view of the 
problems and challenges in regard to resistance. 
 
Theory 
 
“We must embark on a bold new program for making the benefits of our scientific advances and 
industrial progress available for the improvement and growth of underdeveloped areas. The old 
imperialism – exploitation for foreign profit – has no place in our plans. What we envisage is a 
program of development based on the concepts of democratic fair dealing.” (Sachs: 2010, 1) This 
statement from president Truman in 1949 advocated a new paradigm for development. No more 
exploitation for foreign profit, but a concept of democratic fair dealing towards the 
“underdeveloped areas”. Andre Gunder Frank and Immanuel Wallerstein contested this paradigm 
with their dependency theories. In Frank’s article “the development of underdevelopment” (1966) 
He advocates that the developed countries exploit the underdeveloped countries. He calls it a 
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satellite system. Where the developed countries functions as the metropolis and the underdeveloped 
is their satellites, which they extract resources from. The underdeveloped countries are being 
satellized by the superior Metropolis. (Frank: 1966)  
“When we examine this metropolis-satellite structure, we find that each of the satellite, ...., serves 
as an instrument to suck capital or economic surplus out of its own satellites and to channel part of 
this surplus to the world metropolis of which all are satellites” (Frank: 1966, 20)  
He explains that the underdeveloped satellites throughout history have experienced the best 
economic development when their ties to metropolis where weakest. (Frank: 1966, 24) Which are 
quite interesting, and a question that has contemporary significance today. A general assumption 
today, is that underdeveloped countries need to have some form of tie to the developed world in 
order to develop. Frank’s call to change the metropolis-satellite structure lies at the new generation 
of scientist from the underdeveloped countries. “.... themselves who most need to, and best can, 
devote the necessary attention to these problems ... in the last analysis face the task of changing this 
no longer acceptable process and eliminating this miserable reality” (Frank: 1966, 30)  
Wallerstein’s approach draws on historical data, inspired by Marx theory of capitalism exploitable 
surplus labour. In his World-System theory he divide the worlds countries up in a system of three 
categories in relation to the division of labour and the world economic power system: core, 
periphery and semi-periphery. The core countries are superior in terms of skills and technology in 
their production compared to the countries in the periphery and the semi- periphery that are 
focusing on low-skill labour and resource extraction. This division produces inequality for the 
countries that are not in the core. Because the exchanges they do with the latter is unequal and hold 
their country in a fixed position, which makes it hard to develop and escape their status as a 
periphery country. “Once we get a difference in the strength of state machineries, we get the 
operation of ‘unequal exchange’, which is enforced by strong states on weak ones, by core states on 
peripheral areas. Thus capitalism involves not only appropriation of the surplus value by an owner 
from a labourer, but an appropriation of surplus of the whole world-economy by core areas.” 
(Wallerstein: 1979, 19)  
What is antibiotic resistance? 
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Antibiotic resistance happens when the microbes in the body resist the effects of the antibiotic. It 
means that the microbes are not killed, and therefore they continue to grow. Microbes cannot bee 
seen with the human eye and exist in many places on the earth. There exist many different kinds of 
microbes, the one which get’s resistant to antibiotics is bacteria others are viruses, fungi and 
parasites. All together they go under the name antimicrobial resistance. Many microbes are 
harmless and even good for living organism however some of them cause diseases to humans, 
animals and plants. Microbes are often referred to as pathogens, germs or bugs. (CDC: 2015) The 
antibiotic-resistant bacterium spreads through human contact, both through personal contact and 
inhalation of droplets from coughing. (Laxminarayan, Malani, 2007: 3) What has become evident 
today is we see an increasing mutation of microbes, which are evolving and transmitting to other 
microbes. (Gelband…..: 2015)  Many microbes are today resistant to more than one antibiotic, 
which is a problem because newer lines of antibiotic is more expensive and out of reach for many 
people. (Gelband…..: 2015) 
 
Antibiotics are also used in food production on animals and it’s the same cycle of resistance that 
happens there. Use of antibiotics develops resistant bacteria in the animal’s gut. The drug resistant 
bacteria can remain on the meat we later pick up in the supermarket. If the meat is not prepared 
properly the antibiotic-resistant bacteria can spread to a humans host. Even if the meat is cooked 
properly there can be situations where the bacteria spread from a cut board or the meat package 
have been dripping in the refrigerator.  Another way the resistant-bacteria can spread is through the 
environment.  Lakes, wild animals, flies, fertilizers, trucks transporting animals and workers on the 
farm. Basically many things from the farms runoff can transmit the bacteria that have become 
resistant and evolve in other microbes. (C-Union)  
 
Scope of the problem 
 
Every time somebody takes antibiotics you give the bacterial germs a better change to develop 
resistance. This is why many regard antibiotics equally to natural resources like oil, fish and forest. 
They see it as a precious common pool resource, which should be used and coordinated on a global 
level. (Outterson, 2014: 7) (Laxminarayan, Malani, 2007: 1) As Laxminarayan and Malani puts it: 
“All antibiotic use, appropriate or not, ‘uses up’ some of the effectiveness of that antibiotic, 
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diminishing our ability to use it in the future” (Laxminarayan, Malani, 2007: 1) Boosting the speed 
in which we become resistant by overuse shares the same resources problems as global warming or 
overfishing. (Laxminarayan, Malani, 2007: 1) 
 
The recent report on world antibiotics situation 2shows that we on a world basis experience an 
overall decline in the effectiveness of antibiotics – resistance to all first-line and last-resort 
antibiotics is increasing. The patterns of which bacteria becomes resistant to specific antibiotics 
differ regionally and by country. Between 2000 and 2010, the total global antibiotic consumption 
grew with 30 %, approximately from 50 to 70 billion units based on data from 71 countries. 
3(Gelband….., 2015: 10) In general the per capita consumption is higher in high-income countries; 
however from the above time frame the biggest increased in consumption happened in low and 
middle-income countries where consumption continues to rise.  Data are much more rich in the 
developed countries where systems has been running in many years to monitor antibiotic resistance 
than in the developing world. In the US is estimated that antibiotic resistance is responsible for 2 
million infections and 23.000 deaths each year. In Europe data estimates 25.000 deaths each year to 
antibiotic resistant. Data from the developing world is scarce but it’s estimated that in India alone 
the world’s biggest user of antibiotics has 58.000 deaths in newborn children diseases related to 
resistance. (Gelband….., 2015: 8) 
 
In the latest WHO report on antimicrobial resistance (WHO, 2014:) they find Escherichia coli, 
Klebsiella pneunomiae and Straphylococcus aureus (MRSA) bacterias of greatest concern. There 
was reportedly resistance to E. coli to fluoroquinolones antibiotic and third-generation 
cephalosporins antibiotic up to 50 % in 5 out of the 6 WHO regions. K. pneumonia had resistance 
rates to cephalosprins up to 30 % in average WHO member countries and exceed 60 % in some 
regions. MRSA experienced resistance rates exceeding 20 % in the 6 WHO regions and 80 % in 
some regions.  (Gelband….., 2015: 18) The report concluded that there is a high rate of resistance to 
first and second line drugs, which is leading to a reliance on last-resort drugs, such as carbapenems. 
This is problematic in the developing world because access to the last line of antibiotics that works 
is expensive and out of reach. 																																																								
2 The state of the world’s antibiotics 2015: CDDEP the center for disease dynamics, economics & policy, Washington 
DC, New Dehli (https://cddep.org/sites/default/files/swa_2015_final.pdf) 
3Between 2000 and 2010, antibiotic consumption increased by 36%. Five countries, Brazil, Russia, India, China and 
South Africa (BRICS) accounted for 76% of this increase in antibiotic consumption. 
(http://resistancemap.cddep.org/key-findings) 
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Experts in the field seem to agree on 3 big areas to explain why we experience this antibiotic 
resistance. (CDC) (Gelband…..: 2015) (Laxminarayan, Malani, 2007)  Firstly the inappropriate use 
of antibiotics. Secondly the world don’t have a strong enough global surveillances system to track 
and rapport and coordinate between nations. Lastly we don’t spend sufficient enough on R&D in 
order to have new promising products in the pipeline. The recent report on the worlds antibiotic 
situation (Gelband……, 2015: 8 ) points furthermore to two worldwide trends that are up scaling 
the resistance problem. Higher incomes particular in the middle-income countries results in 
increasing access to antibiotics. The higher incomes are equal to increased prosperity and 
population growth, which yields a higher demand for animal products. Farmers are transitioning to 
a more intensive food production system where antibiotics are used to optimize production.  
 
Inappropriate use of antibiotics 
 
The inappropriate use of antibiotics happens when people are given antibiotics when they don’t 
need it for their particular condition. There are many incidents where this occurs. The biggest driver 
is that in many parts of the world primarily in the developing world you don’t need a prescription in 
order to get hold of antibiotics. This over the counter problem creates a huge misuse and overuse of 
the drug. (Gelband……, 2015: 8 ) 
 
Many people take antibiotics without being sure it’s the appropriate medicine for them due to the 
way antibiotics is perceived. When penicillin and other antibiotics entered the scene back in the 
days, they changed the landscape for medicine. They cured diseases with minimal side effects and 
were perceived as wonder drugs. This image of antibiotics has somewhat clung to modern day. We 
therefore see many people taking antibiotics wrongfully and people pressing their doctors to 
prescribe them with antibiotics to get immediate relief for their pain. The doctor obliges to write a 
prescription, as she wants to please her patient and see it as an action that benefits her practice. 
(Laxminarayan, Malani, 2007: 4) Furthermore there is an absence of clinical training for antibiotic 
treatment for physicians combined with a lack of proper diagnostics to identify the cause and 
susceptibility of an infection.  (Gelband……, 2015: 38)  
There is a financial problem in the inappropriate use particular in the developing world. If you have 
limited resources to buy medicine, then antibiotics seems like a good solution even though you are 
	 9	
not sure it will help. In hospitals there is also a large inappropriate use of antibiotics, A US study 
from 2009-2010 of antibiotic use in 6 US hospitals showed that only 59 % of patients received the 
appropriate prescription of antibiotics. A consistent problem was that there were given broad-
spectrum antibiotics even though a specific microbe was identified. From a resistance point of view 
this is very bad, because these broad-spectrum antibiotics is effective against a wide range of 
microbes and can contribute to the spread of resistant strains of many non-target organism. 
(Gelband……, 2015: 34 ) Research on hospitals use of antibiotics in low and middle-income 
countries paints the same picture. A common culture in these countries is that antibiotics are given 
after a surgery in comparison to high-income countries where the common policy is to give it 
before surgery. Research shows that 7 times more antibiotics are used when you give it post rather 
than pre surgery. (Gelband……, 2015: 39 ) It’s estimated that antibiotics in USA stands for 15-30 
% of the total drug expenditure, which is the largest expenditure of any therapeutic group of drugs.  
(Venkatesh, Bairavi, Sasikumar: 2011) 
 
The professionals in the health sectors are just as the consumer part of the problem, they need to see 
antibiotics, as scarce resources if development has to be better. Obviously not all doctors are like 
this but it’s an area where there is room for improvement. (Gelband……, 2015) In the UK is 
estimated that out of the 42 millions antibiotic prescription each year around 10 million of them are 
inappropriate. (BBC) In the USA the Center for Disease Control (CDC) estimates that 50 % of all 
antibiotics prescriptions are not optimally prescribed.  (CDC) A global statistic on antibiotic use 
shows that 20 % of antibiotics are used in hospitals and healthcare facilities, 80 % are used in the 
community. These 80 % are either prescribed by healthcare providers or bought directly by 
consumers or caregivers without prescription. It’s estimated that roughly half of all community use 
is used inappropriately for instance on coughs and colds where antibiotic will not benefit the 
treatment. (Kotwani, Holloway: 2011 ligger I 2015 report kilde) 
 
Food production 
 
There is a projected increase in antibiotic use in food production due to expected human population 
growth in the future. Meat and other animal products are predicted to almost double in the next 35 
years.  (Gelband……, 2015: 42 ) Antibiotic use in food production has 3 roles. The treatment of 
individual animals with bacterial infections, a prevention mechanism for infections and lastly to 
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promote growth. The first two points is related to human use, the difference is that antibiotics is 
often given to entire herds if one infection is discovered – spreading resistance factor. The growth 
promotion doesn’t have a human counterpart and accounts for most use and fear in regards to 
resistance. The global antibiotic use on animals was 63.200 tons in 2010, this accounts for nearly 
two-thirds of the estimated 100.000 tons antibiotic produced annually worldwide. By 2030 the 
consumption is estimated to rise to 105.600 tons. A US study in 2010 estimated that 80% of all 
antibiotic sold in the country is used in food production. (Gelband……, 2015: 42 ) The effects on 
this massive use on human health have 4 headlines.  
• “Direct animal to-human transmission of resistance 
• Animal food-to human transmission of resistance  
• Food-borne outbreaks of infection 
• Parallel trends in antibiotic use in animals and related antibiotic resistance in humans.”  
(Gelband……, 2015: 46 ) It’s hard to understand the concrete connection between animals and 
humans because there are various transmissible genetic elements that can carry the resistant gene to 
different host of bacteria. However there have been many incidents where resistance patterns have 
showed up in humans coming from antibiotic use in animals. A recent report by Lancet4 with 
fieldwork conducted in China on pigs showed that 15 % of the pigs had developed the gene MCR-
1. MCR-1 is a mutation that prevents the antibiotic colistin to work the last anti biotic to treat 
infections like E.coli. Experts fear that these resistant bacteria will evolved to others and in the end 
give the world diseases where we don’t have antibiotics that work anymore. So the threat for animal 
carrying diseases to humans and develops resistant against antibiotics is a thread we need to take 
serious. Improved hygiene and nutrition on the farms can prevent infections to happen in the first 
place. The growth promotion use is problematic, and there needs to be an international coordination 
to fight this. Many western European countries and in the USA there are policies towards limiting 
the antibiotic use for growth promotion. In 1986 Sweden banned all use of antibiotics aimed at 
growth promotion in animal feed.  Denmark prohibited in 1995 veterinarians from selling 
antibiotics to farmers. Same year they banned two growth promoters’ avoparcin and virginiamycin 
because of some worrisome findings in antibiotic resistance that were discovered in the public. EU 
followed up on Denmark and Swedens regulations and declared in 2003 that most antibiotics as 
																																																								
4 Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a 
microbiological and molecular biological study DOI: http://dx.doi.org/10.1016/S1473-3099(15)00424-7 
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feed additives would not be allowed. This has resulted in an overall decline in the use of antibiotics 
in Europe.  (Gelband……, 2015: 46) 
 
Most concern is the up scaling of farming operations in the emerging economies. Here we see a 
shift to a more professional agriculture production, where large-scale antibiotics are part of the 
production. (Gelband……, 2015: 52) 
 
It’s hard to get a global common policy for the use of antibiotics because antibiotics are used and 
bought differently in the world. In developing countries where resources are scarce antibiotics may 
be the only medicine they can afford, making it hard to make stricter laws on antibiotics compared 
to the west. However it’s an area where governments on a national level have to implement more 
severe rules and enforce global collaboration on the issue of inappropriate use. The global antibiotic 
resistance partnership (GARP) has developed 6 national antibiotic policies to improve the 
effectiveness of antibiotic and limit resistance: 
 
1. “Reduce the need for antibiotics through improved water,  sanitation, and immunization.   
Improving coverage for existing vaccines and adding new ones, improving access to clean water 
and sewerage systems, and ensuring a safe and healthful food supply all reduce the need for 
antibiotics, thereby reducing antibiotic resistance rates.   
2. Improve hospital infection control and antibiotic stewardship.   
Better hygiene, particularly hand washing with soap or using alcohol disinfectant between patients, 
and antibiotic stewardship programs reduce infection rates. Surveillance of resistance and 
hospital-acquired infections gives administrators information for management and policy decisions. 
  
3. Change incentives that encourage antibiotic overuse and misuse to incentives that encourage 
antibiotic stewardship.   
Eliminating economic incentives that encourage the overuse of antibiotics all along the supply 
chain—in hospitals, in communities, and in agriculture—can conserve antibiotic effectiveness.   
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4. Reduce and eventually phase out antibiotic use in agriculture.  
Eliminating antibiotic use for growth promotion and minimizing use for disease prophylaxis need 
not jeopardize animal or human health.  
5. Educate and inform health professionals, policymakers, and the public on sustainable antibiotic 
use.  
Education and guidelines for healthcare professionals, engagement with policymakers, and 
national awareness campaigns for the public will begin changing the norms in antibiotic use and 
promote conservation.  
6. Ensure political commitment to meet the threat of antibiotic resistance.  
Presenting the case to policymakers and gaining their political and financial support are critical to 
success. “ 
(Gelband……, 2015: 16 ) 
 
In the long run the use of antibiotics has a subjective human nature – the tension between individual 
good and the collective good. It would be good for the course if people on earth perceived 
antibiotics as a scarce resource and a more collective good. (Laxminarayan, Malani, 2007: 3) The 
social norm needs to be changed a recent social norm we have seen change in some parts of the 
world with success is cigarette smoking. This shows that it is possible to change a social norm.  
 
The development of new medicine is a long and very expensive process. The time period from 
starting in the lab to getting the medicine out on the market is approximately 12 years. The average 
cost of producing a new medicine is estimated to be one 1 billion or more.  (Gelband……, 2015: 61 
) This is an estimate from the pharmaceutical industry. The pharmaceutical industry often receive a 
lot of negative attention for putting high prices on their medicine they defend themselves with 
arguing that the prices is reasonable because they spend so much on R&D. The transparency of the 
actual cost of the production of a new medicine is limited. It’s therefore hard to know how 
expensive it is. There has been much research on this topic and it’s a very controversial. Because of 
the high prices connected with producing new medicine, the pharmaceutical companies need a 
financial incentive to start producing a new medicine. (Muzaka: 2011) This has received much 
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criticism over the years because many diseases become neglected. This is particular true in diseases 
that are found in the developing world. A big group of them is called neglected tropical diseases  
(NTD) and consist of 17 diseases. (WHO 2) A recent example of this financial incentive that drives 
the pharmaceutical industry was evident in the recent Ebola outbreak. The first outbreak of Ebola 
occurred in 1976 and have killed and had economic consequences for areas in West Africa. No 
pharmaceutical company have had any interest in developing medicine before it became a threat for 
people in rich countries. Now there are promising vaccines on the way to the market with soon to be 
released. 5 When it comes to the development of new antibiotics experts argue that there are missing 
incentives for the pharmaceutical companies. Antibiotics offer a poorer return on investment than 
other drugs. People only use them few times in a short period, in comparison to other medicines for 
chronic conditions. New antibiotics are priced lower than other new drugs. The clinical trials are 
said to be more expensive than average clinical trials, because there is more testing involved. Then 
there is the risk of the antibiotic to become useless if bacteria become resistant to it. Physicians who 
treat infections diseases with new antibiotics try hard to protect the effectiveness of the drug so we 
don’t get an overuse that speeds resistance. (Venkatesh, Bairavi, Sasikumar: 2011)  (Gelband……, 
2015: 59-60)   
 
Development of new antibiotics 
 
There seems to be different opinions about the importance of putting more resources in the 
development of new antibiotics. WHO have in a recent report from 2012 on antibiotic resistance 
declared that it is very important that we put immediately global attention in coming up with other 
models to produce antibiotics when the current incentive for the pharmaceutical industry is weak. 
(WHO 3, 2012: 83) In the report ‘extending the cure’ a policy report for governments they argue for 
focus putting more resources in R&D of antibiotics with the argument that antibiotic resistance 
cannot be prevented; it will happen eventually – it is the survival of the fittest mechanism that exists 
in bacteria. (Laxminarayan, Malani, 2007: ) The antibiotic report from (Gelband……, 2015:) finds 
in contradiction to the other reports that the antibiotic pipeline is good and healthy. “Contrary to a 
view that predominates in policy discussions, the antibiotic pipeline is healthy and continually 
producing antibiotics in the absence of incentives to encourage development. “(Gelband……, 2015: 
64) They explain that in 2014, 7 new antibiotics entered the market. In 2014, 37 new antibiotics 																																																								
5 http://www.who.int/medicines/emp_ebola_q_as/en/ 
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were in the development pipeline for approval in the USA, 8 of these where in the clinical phase 3 
(the last stage before approval). They emphasise that it’s more important to focus on the 
conservation of antibiotics and improve access: “lack of or delayed access to antibiotics still kills 
more people than resistant infections. To achieve the maximum benefits to human health, measures 
to reduce inappropriate use of antibiotics must be combined with efforts to improve access when 
they are needed.”  (Gelband……, 2015: 39)  
Getting access to antibiotics can be difficult in rural areas and in 2013 pneumonia caused 935.000 
deaths for children under 5. (Gelband……, 2015: 33) The reason for this is due to poor public 
health infrastructure and difficulties in logistics. Another challenge in terms of access is making 
sure that new antibiotics are accessible for developing countries. New medicines including 
antibiotics are know to be more expensive when they are first released and still under patent. When 
more and more antibiotics are loosing their effectiveness because of resistance it means that future 
generations in developing countries can experience problem with getting access to the newer lines 
of antibiotics due to high prices. In order to fight resistance is important if new and more effective 
antibiotics are available that they are used instead of inappropriate use of other antibiotics that don’t 
cure but rather boost resistance. (Gelband……, 2015: 34) The rules regarding this problem with 
access lays within the international law set on intellectual property rights called TRIPS which sets 
the rules for patens and generic medicine. In the next section I will explain how the TRIPS works 
and what can be the complications for developing countries and what options they have. 
The TRIPS agreement: 
 
“If new knowledge and technologies were freely available, and capable of being copied by others, 
the incentive for private actors to invest in their development would be very weak. Patent law seeks 
to solve this problem with a period of exclusivity, effectively turning knowledge into property for a 
limited time. “ (Outterson 2014: 8) 
 
The TRIPS agreement stands for: The Agreement on Trade-Related Aspects of Intellectual Property 
Rights. This agreement is the international law set on how patents works which is applied to 
antibiotics. To get an understanding of how and why the rules are like they are I will start by 
outlining the historical events leading up to the creation of the TRIPS in WTO in 1995. 
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We saw a change in the economic landscape from material to immaterial goods, a shift from 
industry to knowledge-based economies. New innovation resulted in new products and production 
patterns from the beginning of the 1980’s. International trade was booming and countries were 
trading over large distances. This created a new demand for companies to protect their products and 
ideas from counterfeiting products in overseas markets in particular where control was harder to 
achieve. This resulted in the creation of the TRIPS agreement in 1995 which was implemented in 
the newly establish World Trade Organization. Before the WTO came into play with TRIPS is was 
GATT (General Agreements in Tariffs and Trade) that handled rules and disputes over intellectual 
property rights. The big difference between GATT and WTO-TRIPS is that GATT did not have a 
dispute settlement system as WTO has. Which meant that disputes were handle bilateral between 
countries. This resulted in a situation where more powerful countries in terms of economic and 
political power had more leverage and dominated the disputes especially if the dispute where 
between a developed and developing country. (Muzaka: 2011)  
 
Prior to the agreement the large industries that operated with intellectual property in their line of 
business had successfully lobbied their national governments to put pressure for a strong agreement 
to enforce intellectual property rights. (Muzaka, 2011: 48) 
 
The rules of the TRIPS are like any other international law complex and hard to navigate in. The 
most important rule and relevant to access issues for developing countries is that if a pharmaceutical 
company is granted a patent through the relevant authorities Food and Drug Administration (FDA) 
in USA for instance. If approved they receive a patent the last for 20 years and give them monopoly 
on the rights.  (Muzaka: 2011) They also have the freedom to decide the cost of the medicine. This 
often results in prices that are too high for many citizens in the developing world to afford. From a 
public health point of view this is very problematic. Before the TRIPS agreement came into play 
around 50 countries did not grant patent protection, including developed countries like Spain and 
Portugal. (WHO 4) When there is no patent protection in place it means that a country can use 
generic medicine in their hospitals and in the community.  
 
Generic versions are a much cheaper and good alternative for developing countries, with limited 
funds in their health budget. A generic medicine is a faithful copy of a mature drug, which is no 
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longer under patent. (Venkatesh, Bairavi, Sasikumar: 2011) The generic medicine plays an 
important role to the overall health in the world. On the demand side generic drugs are helping the 
growing expenditures in health care. On the supply side it offer price competiveness to the more 
expensive patented product, which has resulted in many essential medicine seeing a drop in prices. 
(Venkatesh, Bairavi, Sasikumar: 2011)  A research conducted in 2008 showed that on an average a 
patented prescription drug was 4 times higher than a generic version. (Venkatesh, Bairavi, 
Sasikumar: 2011) On average the first generic competitor that enters the market after the patent runs 
out only offers a slightly reduction in price. The second generic reduce the price 50 % on a average 
hereafter the prices are slowly going down as more and more generics producers start to produce it. 
Very popular products with a large number of generics put the price down to 20 % or lower of the 
branded drug. (Venkatesh, Bairavi, Sasikumar: 2011) 
After the TRIPS agreement came into force countries all over the world especially in the developing 
part experience problems with getting access to essential medicine. (Muzaka: 2011) The question 
that comes to mind is why did the developing countries sign on the TRIPS agreement in WTO, 
when they knew it would properly be devastating for their health.  The main argument for the 
reason is that even though the developing countries new it would have consequences for their 
health, the consequences for not being part of WTO where greater. If they did not sign the deal on 
TRIPS they would not be part of the ‘club’ where there are crucial advantage for their economies in 
terms of exporting their goods to lucrative markets in the west. (Muzaka, 2011: 56) There is also the 
element of keeping good relations with the superpowers in the west. Many developing countries are 
dependent on the funds they receive from aid, not being part of the TRIPS could jeopardize this. In 
the negotiations up to the TRIPS the first draft was opposed heavily by the developing countries 
especially India and Brazil who had good functioning generic industries with good production 
capabilities. They had concerns over what the implementation of a rule set on intellectual property 
would mean for their industry. During the negotiations the developed countries put pressure on the 
developing countries through bilateral trade sanctions. An example of this was when the US 
pharmaceutical manufacturers association filed a complaint against Brazil. They believed that 
Brazil did not life up to the agreements they had on patent control for US drugs and wanted Brazil 
to join GATT in order for them to protect their drugs on the Brazilian market better. The US 
pressured the Brazilian government by putting a 100 % tariff increased on some Brazilian exports to 
the USA. Brazil joined GATT approximately a month after because of the increased tariff, which 
was estimated to cost the Brazil 39 million dollars. (Muzaka, 2011: 56) There are many other 
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examples of trade pressure put on the developing countries in order to sway them in their wanted 
direction. (Muzaka, 2011: 58)  
 
In the 1980’s the developing countries experienced the so-called structural adjustment period, 
where demands form IMF and the World Bank forced them to change internal policies to get depth 
relief and a continuation of funds from the institutions. One of the most important parts was the 
emphasis on the capacity for the developing countries to have a strong export industry. Getting 
access to northern markets for export products like textiles and agricultural products where 
essential. (Muzaka, 2011: 58) The negotiations of TRIPS is from observers point of view a situation 
where the developing countries where faced with a “take it or leave it desicision” (Reichman, 
2009: 2). If you take into account the difference in bargaining power, it’s no surprise that the 
outcome of the agreement was in favor to the developed countries with strong industries operating 
with intellectual property. (Muzaka, 2011) An important actor from the private sector negotiaters 
Jaques Gorlin who was part of writing the draft for the TRIPS responded:  “we got 95% of what we 
wanted” (Muzaka, 2011: 58)  
The first serious challenge to the new TRIPS agreement came into force under the HIV pandemic in 
the late 1990’s in Africa. At this time millions of Africans people where infected with the disease 
and people where dying because they could not get access to antiviral medicine which Pfizer had 
the patent on. The patented drug was priced at 12.000 $ for a single treatment, which obviously was 
out of reach for the average African citizen. At the same time Cipla an Indian generic 
pharmaceutical company offered the same drug for 800 $.  Because of the rules in TRIPS the 
African countries were not allowed the cheaper alternative from Cipla due to Phizer’ patent. Even 
after this came into the public knowledge Africans were still denied access. The founder of Cipla 
Khwaja Abdul Hamied eventually went to Brussels where the European Comission had a meeting 
with large pharmaceutical companies. Here Hamied told them about his achievement of producing 
the HIV drug for 800 $ and offered them to help them with the technology for producing to this 
prize in order to help the African countries, no pharmaceutical company wanted his help. (business 
standard) Eventually the civil society managed to put enough pressure on the pharmaceutical 
industry to let the generic version enter Africa.   
This was a big victory for civil society and NGO’s working with access to medicines. Following 
this an amendment was made in the TRIPS agreement in 2001 called the Doha declaration. It gave 
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the member countries the freedom to determine themselves when they could issue a compulsory 
license for a specific medicine if their public health was in danger. A compulsory licensing is: 
“Compulsory licensing is when a government allows someone else to produce the patented product 
or process without the consent of the patent owner. It is one of the flexibilities on patent protection 
included in the WTO’s agreement on intellectual property.” (WTO 1) This means that a generic 
producer is allowed to produce a cheaper version of the patented drug by paying royalties to the 
originator. This is a very important flexibility in the TRIPS agreement however history has showed 
that not many countries have used this policy option. Simply because they are afraid of the 
consequences from the pharmaceutical companies host country. (Muzaka: 2011) It was also written 
into the new agreement that: “that the TRIPS agreement should be interpreted and implemented in 
a manner that promotes access to medicines for all”  (WTO 2) 
The problem with the TRIPS agreement is contrary to what the agreement upholds that it should 
promote access to medicine for all numerous cases just as the HIV case shows the opposite. In order 
for ensuring access to future generations of antibiotics, both in saving life but also combating the 
rising resistance a discussion and review of the current TRIPS agreement seems convenient.  There 
has not been a lot activity in the WTO recently; the organization is in a stall mate due to India’s 
rejection of accepting rules on food stockpiling and agriculture subsidies. Many observers say that 
we might face an end of the multilateralism in trade and are moving towards a more bilateral 
approach. (Muzaka, Bishop: 2015)  
A recent trend is called TRIPS plus agreements. This is where bilateral trade agreements 
incorporate new rules about pharmaceuticals between the two countries. This could for instance be 
an extension of patents lifetime which would delay generic entrance. These rules made bilateral are 
overruling the rules in the TRIPS which to some extend have flexibilities for the developing 
countries to safeguard their public health. Developing countries sign these bilateral agreements 
because they need advantage in exporting and importing of goods, however it’s very dangerous for 
a public health perspective. (El-Said and El-Said: 2008) 
Alternatives models 
 
As mentioned earlier in the paper some experts on the area believe that antibiotics should be treated 
like any other exhaustible resource. Efficient management of scarce resource needs global 
coordination and the right balance between conservation and production of new antibiotics. Under 
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normal economic theory on drugs sales volume and the price of the product determine the return of 
investment. When it comes to antibiotics this theory is not optimal because maximizing sales is a 
driver for resistance. (Outterson 2014: 8) Delinkage models of finance is where you remove the link 
between the cost of R&D and sales volumes. Through delinkage models companies are paid for 
their R&D cost differently. Delinkage attempts to solve 3 main problems with normal market-
driven R&D: 
 
“Inadequate market incentives for companies to invest in R&D and bring new products to market at 
the right time;   
Inadequate market incentives to protect these valuable resources from overuse and premature 
resistance; and   
Inadequate market incentives to ensure global access to life-saving antibiotics”   
(Outterson 2014: 8) 
From a global public health perspective it’s relevant that delinkage models fulfills different targets 
simultaneously. Inspiring to prevention and control of diseases, the conservation of antibiotics, new 
production and improved access when needed. (Outterson 2014: 18) Until now there has been 
discussed different incentives for companies on the production of new antibiotics, however they are 
not delinkage models if they don’t remove the normal structure where companies are paid on the 
basis of their sales volume. They require a totally new business model with key components as: 
• “Delink revenues from sales volume;   
• Increase total company revenues for antibiotics 
• Encourage long-term global coordination by stakeholders 
• Preserve and enhance access without regard to ability to pay 
• Condition some payments on conservation targets  
• Provide additional revenue streams for prevention, conservation and access in low- income 
populations, which are chronically underfunded in current systems without sustainable 
business models.  ” 
(Outterson 2014: 18) 
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The WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual 
Property have come up with 24 proposals for consideration. Of the 24 proposals only some have a 
100% delinkage formular mentioned above.  
Patent buy-out prize funds – Here the public, for instance a national government buy the patent 
from the pharmaceutical company and can hereby distributed it. They do that by offering a prize to 
the pharmaceutical company that develops the given needed antibiotic. If there is missing an 
important antibiotic for a specific disease then a prize could be won for the company that develops 
the product. It would properly be in the area of 500 – 2 billion $ depending on the R&D process. 
Milestone payments could be integrated and information asymmetries between the companies and 
the prize fund could have an important feature. (Outterson 2014: 21) 
The strategic antibiotic reserve (SAR) – This model is only focusing on exceptionally valuable 
molecules getting ready to enter the market, but where the clinical need is in the future. A 
government or a group of governments would buy the patent for a generous price and safe it when 
really needed. SAR would work as a global insurance mechanism, as nobody know where the 
magnitude of resistance in the future this insurance policy should be given more attention. 
(Outterson 2014: 21) 
Payer licenses – This model delink trough a contractual mechanism between the Drug Company 
and relevant private and public payers. Instead of reimbursing, which is based on unit prices and 
unit volumes; the payer license would before sales negotiate a fixed payment for an antibiotic or an 
array of antibiotics owned by the company. The antibiotics would then be distributed without 
thinking about unit payments. Important for the model is that there is a mechanism established to 
prevent overuse, by making sure that each marginal unit is free to the user. In order to make sure 
that there is an incentive to commit funds to R&D funds, a payer license model must be organized 
years before the antibiotics are used. 
Developing countries most likely don’t have the capability in their governments to use some of 
these models. Therefore for them using an independent stakeholder to control the intellectual 
property including the licenses would be necessary. An independent stakeholder could be the 
Medicines Patent Pool. (Outterson 2014: 27) Started by access to medicine champion Ellen T’ Hoen 
is a organization who make agreements with drug companies to license their patent on a drug in 
order to distribute drugs too developing countries at a more affordable price. (medicinespatentpool) 
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How do we coordinate delinkage models on antibiotics? WHO would be a relevant institute as its 
role is the overall coordinating institute for global health. The framework convention on tobacco 
has been very effective. In comparison to the world health assembly’s where there are no 
consequences for countries if they don’t uphold given policies. Coordination does not mean that 
each country most follow the same means to reach the goal. Countries should choose the delinkage 
models that suits them best. What would be good would be if key markets agreed on common goals 
and pursue them locally. For example EU and USA together counts for 2/3 of the worlds use of 
antibiotic, if they could agree on a coordinated plan for hospital use for instance they positive 
spillovers could emerge for other countries. (Outterson 2014: 27) 
Finance for alternative R&D models 
 
The problem with high prices in medicines due to private companies have the monopoly and is 
steered by commercial interest has been an issue for many years; the above-mentioned TRIPS 
agreement has boosted this problem. Bill gates the biggest contributor to tropical diseases R&D 
illustrate the paradox of the worlds focus in R&D: “Our priorities are tilted by marketplace 
imperatives, the malaria vaccine, in humanist terms, is the biggest need, but it gets virtually no 
funding. If you are working on male baldness or the other things you get an order of magnitude 
more researching funding because of the voice in the marketplace” (TheAtlantic) Solutions on how 
to overcome this gap in R&D has been many, most successful have been public-private 
partnerships. However a proposed global R&D treaty has been under the way since the first meeting 
at WHO in 2012. WHO had put a working team together to come up with solutions to overcome the 
gaps in R&D on medicine. The Consultative Expert Working Group on Research and Development 
(CEWG) concluded in their report that the best way to address this problem was to negotiate a 
medical R&D treaty. This could be a potential game changer and could lead to sustainable solutions 
within financing, monitoring and coordination of R&D in essential medicine including antibiotics.  
CEWG purposed that every member country joining the treaty should contribute minimum 0.01 % 
of their GDP to a shared pool devoted to meet the health needs of developing countries. The pool 
would also be open to voluntary public, private and philanthropic contributions. In order to secure a 
sustainable and appropriate level of funding, the CEWG recommends that member states sign a 
treaty so the commitments would be binding. In the recommendations the CEWG also has proposed 
similar delinkage models for the production of new medicine as described above with antibiotics. 
(WHO 5) 
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The negotiations in 2012 were suspended and are schedule to be taken up again in March 2016. In 
the end it was the pharmaceutical companies and it’s allies that were the reason for the 
postponement. They considered that the R&D treaty proposal of de-link medicine prices from R&D 
costs would undermine patents and jeopardized the industry. USA the single largest funder of 
neglected disease R&D where also hesitant, it stated that it would not: “support any proposal that 
would put in place a new financing mechanism that could be characterized as a globally collected 
tax” (Kiddell-Monroe, Iverson, Gopinathan, 2013: 2)  
Observers of the negotiations at the meeting in 2012 are questioning WHO global health leadership. 
The CEWG promoted a transparent process with the possibility for civil society to participate in the 
negotiations. What happened at the negotiations was quite different. The intergovernmental 
organizations where shut out of both policy and decision making processes. Civil society where 
excluded from all sessions at the open-ended meeting except the first morning session. 
WHO failed to fulfill it’s own recommendations from CEWG to establish a new treaty and it cast 
doubts on WHO’s ability and it’s member states to work in the best interest of vulnerable countries 
populations. (KEI, 2013) In the same letter Knowledge Ecology International a pioneer NGO in 
access to medicines writes: “Such a global framework is needed to establish a process for 
identifying R&D needs, setting priorities, monitoring R&D flows, coordinating R&D efforts, 
securing sustainable financing, promoting new incentives and managing research outputs in a way 
that ensures both innovation and access. Given the WHO’s role as the directing and co-ordinating 
authority in global public health, it is uniquely placed to be the forum for such an instrument.”  
Strategy for releasing new antibiotics 
 
Besides the importance of these delinking models there is also the importance of a global 
coordinated strategy for the way we release antibiotics to the market and making sure we don’t 
release antibiotics that don’t have a scientific improved clinical effect.  (Outterson 2014: 8) From 
1980 – 2009 FDA approved a decreasing number of antibiotics for priority review6. The antibiotics 
class of medicine has 3 times more withdrawals from the market than average medicine 26 out of 
61 antibiotics in the above period. (Outterson 2014: 13) Most of these antibiotics did not have an 																																																								
6 ”Priority review is given to drugs that are expected to treat serious conditions and provide significant improvements 
in safety or efficacy over existing therapies.” (Outterson 2014: 8) 
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improve effect in medical results. 6 were removed due to safety related issues.  Incentives should be 
on producing high quality antibiotics with severe improvement in effect.  
“A small number of outstanding new antibiotics would be a much better outcome than a large 
number of undifferentiated antibiotics without enhanced efficacy and safety in serious or life-
threatening conditions. Rewards should be concentrated on the best drugs and unnecessary drivers 
of resistance should be minimized.”  (Outterson 2014: 13) 
If the pharmaceutical industry had developed many high-quality antibiotics and it was ready to be 
released to the market at the same time this would not be wise due to resistance. In other drug 
classes like cancer, then if a new product had a significant effectiveness and the price was 
affordable then it should obviously be released as fast as possible as it would benefit the public. 
Outterson argues that this is not the case for antibiotics: 
“The same may not be true for antibiotics. Introducing 10 high-quality novel antibiotics in one 
decade will jump-start the evolutionary process of resistance for all of them. “  Rather than have 10 
antibiotics enter the market simultaneously, it may be more appropriate for society to generate only 
a few high-quality antibiotics per decade, based on clinical need as resistance progressed. 
Unfortunately, the current incentive framework does not permit this option.  
(Outterson 2014: 14) 
World health organizations role 
 
 
WHO is the global coordinator of the world’s health, the organization has through out the years 
received critics for being biases towards specific interest from primary the west. Recently there 
have been a lot of critics in the way they handled the Ebola epidemic and the bird flu outbreak in 
China. The affected states are withholding the real numbers and fears from the public in order to 
protect their trade and tourism. They reacted to late observers argue, they had all the relevant 
information to put the countries in quarantine. (Garrett: 2015) In the recent Ebola outbreak WHO 
hesitated to declare it a global crisis, the argument was that it should only be done as a last resort. 
However it did not take long before the first infected person hit US ground to be declared a global 
crisis. This puts into consideration the power relation between the west and south. The world closed 
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its boarders and the international flight union was restricted to fly in and out of the affected 
countries. This turned out to be a bad idea because it delayed the establishment of supplies to the 
countries – only UN flights were allowed.  (Garrett: 2015) Lawrence Gostin a global health 
professor: 
 
"A rapidly transmitted disease in the world's poorest countries, that's what WHO was created for, 
and it just utterly failed," he says. "It was unconscionable." 
(NPR) 
 
Another critical point in the critic of WHO leadership and role of global health coordinator is their 
budget. In the 2014/2015 budget 77 % came from voluntary contributions from member states and 
other donors. Voluntary donations often have earmarked priorities, which is conflicting for WHO to 
take their own decisions. Basically their donors pull them in different directions, which is 
problematic when it comes to defending public health and not some wealthy states interest. 
(ScienceAmerica)  
 
When it comes to defending the developing countries right to access to essential medicine, the 
developing countries are up against powerful nations interest to protect their pharmaceutical 
industry who are know for being good at lobbying politicians. WHO function should be to pressure 
the powerful nations for better deals for the developing countries as WHO is the global health 
institute that looks after it’s members – rich or poor. This stand can be problematic for WHO when 
there policy options are affected by earmarked funds. One can therefore conclude that when it 
comes to the whole access to medicines and affordable prices on antibiotics for developing 
countries – how much are WHO helping them? Properly they want to help them more but they 
cannot. (Kiddell-Monroe, Iverson, Gopinathan, 2013:) This funding situation could have played a 
role in the postponement of the international R&D treaty.   
Sum up 
 
It’s understandable that making a global coordinated effort on fighting antibiotic resistance is 
difficult because of the scope of the problem. The key to success seems to find the right balance 
between conservation of antibiotics through appropriate policies for use and the development of 
	 25	
new antibiotics. If you look at it from a economical perspective the US Center for disease control 
(cdc) has in recent years spent about 5 million $ on antibiotic conservation. (Gelband……, 2015: 
61) If the discovery of a new antibiotic cost around 1 billion $, it seems like there should go more 
resources to conservation. As Dennis Maki working with infectious diseases put it: “The 
development of new antibiotics without having mechanisms to insure their appropriate use is much 
like supplying your alcoholic patients with a finer brandy.” (Outterson 2014: 14) The finance of 
new antibiotics has challenges in the future. However the focus on delinkage models is interesting 
and could become a game changer in the field. How to make sure that these developments both in 
conservation policies and new lines of antibiotic also benefit the developing world is challenging. In 
order to solve this problem, The World Health Organization has an important role to play as the 
global safeguard for public health. The civil society plays an important role for advocating the 
developing countries right to health as we saw in the negotiations of the R&D treaty. They will 
continue to fight for the most vulnerable populations, which is needed in a highly political world 
where powerful nations often gets away and not hold responsible for their damage. 
Conclusion: 
 
The project has showed that there are many drivers to antibiotic resistance. The creator of the first 
antibiotic already at that time pointed out that we needed to watch out for resistance. Taking that 
into perspective it seems like the worlds society has been neglected this problem to long. 
Inappropriate use is highly common in developed countries just as in developing countries. So this 
is not a question about how many resources you have. It should be possible for USA and Europe to 
develop more responsible policies for use of antibiotics in hospitals. Use of antibiotics in agriculture 
pose a significant thread to human kind. Rising income in many parts of the world is resulting in 
higher demand for animal products. A global effort is needed here as well as resistance can spread 
to humans.  
The delinkage models for new development of antibiotics could be a game changer together with 
the R&D treaty. Regarding access to antibiotics, the rules of patents in the TRIPS should be revised 
in order to find the right balance between benefits for the pharmaceutical industry and countries 
with poor economic resources.  
Antibiotic resistance is hard to coordinate due to the governance of global health is built up by a 
regime of different interest. However finding a common ground to develop the right policies to 
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combat antibiotic resistance is essential for future generations. Just like any other global policy if 
it’s not a hard law and countries can be hold accountable it’s easier for them to slip away. Also the 
coordination of any global health effort is complicated because there is no global government. The 
global health government consist of so many different players both private and public. Time will 
tell if the World Health Organization can steer the world towards better antibiotic resistance 
behaviour. No matter their effort it also seems evident that an individual effort is needed from 
doctors to citizens around the world. 
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